

CITATION REPORT

List of articles citing

Tau and A β 42 in Cerebrospinal Fluid from Healthy Adults 21-93 Years of Age: Establishment of Reference Values

DOI: 10.1093/clinchem/47.10.1776
Clinical Chemistry, 2001, 47, 1776-1781.

Source: <https://exaly.com/paper-pdf/32632616/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
391	Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. 2002 , 14, 183-90		47
390	Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. 2002 , 58, 1622-8		150
389	Biomarkers in Psychotropic Drug Development. 2002 , 10, 678-686		5
388	Evolution and the scientific method. <i>Neurobiology of Aging</i> , 2002 , 23, 1093-5	5.6	1
387	Biological markers of Alzheimer's disease. 2002 , 56, 74-84		9
386	Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. 2002 , 28, 427-40		29
385	Cerebrospinal fluid tau protein levels in schizophrenia. 2003 , 253, 100-2		15
384	Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. 2003 , 72, 132-6		53
383	Atypical dementia associated with a novel presenilin-2 mutation. 2003 , 54, 832-6		48
382	Vascular parkinsonism in moyamoya: microvascular biopsy and imaging correlates. 2003 , 54, 836-40		9
381	CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. <i>European Journal of Neurology</i> , 2003 , 10, 119-28	6	51
380	Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. <i>Neuroscience Letters</i> , 2003 ,	3.3	
379	Cerebrospinal fluid markers for prediction of Alzheimer's disease. <i>Neuroscience Letters</i> , 2003 ,	3.3	
378	Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. 2003 , 16, 136-44		127
377	CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. 2003 , 60, 652-6		444
376	Cerebrospinal fluid markers for prediction of Alzheimer's disease. <i>Neuroscience Letters</i> , 2003 , 352, 67-9	3.3	138
375	Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. <i>Neuroscience Letters</i> , 2003 , 353, 57-60	3.3	81

374	Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. <i>Neuroscience Letters</i> , 2003 , 339, 172-4	33	45
373	Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. 2003 , 61, 243-53		63
372	Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. 2003 , 40, 25-40		82
371	Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. 2003 , 289, 2094-103		453
370	Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. 2003 , 60, 1457-61		177
369	CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. 2003 , 4, 147-55		82
368	Laborchemische Diagnostik. 2003 , 452-466		
367	Zum Stellenwert der Liquoruntersuchung für die Diagnose demenzieller Erkrankungen. 2004 , 31, 223-230		0
366	Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations. 2004 , 42, 396-407		10
365	Frontotemporal dementia: impact of P301L tau mutation on a healthy carrier. 2004 , 75, 1607-10		25
364	Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. 2004 , 62, 1580-4		152
363	Biomarkers in non-Alzheimer dementias. 2004 , 3, 375-381		2
362	Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. 2004 , 9, 705-10		240
361	Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. 2004 , 111, 247-72		101
360	Psychiatric epidemiology of old age: the H70 study--the NAPE lecture 2003. 2004 , 109, 4-18		63
359	Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. 2004 , 25, 2912-8		88
358	Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. 2004 , 19, 554-60		60
357	Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. 2004 , 19, 544-8		156

356	Neuronal globus pallidus activity in patients with generalised dystonia. 2004 , 19, 548-54		42
355	Verb and noun generation tasks in Huntington's disease. 2004 , 19, 565-71		23
354	Grip force abnormalities in de novo Parkinson's disease. 2004 , 19, 560-5		50
353	Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. 2004 , 19, 571-9		76
352	Biomarkers in non-Alzheimer dementias. 2004 ,		
351	Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. 2004 , 56, 670-6		155
350	Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. 2004 , 25, 471-80		16
349	Advances in the Development of Biomarkers for Alzheimer's Disease - From CSF Total Tau and Amyloid-β(1-42) Proteins to Phosphorylated Tau and Amyloid-β-Antibodies. 2004 , 134-156		2
348	Cerebrospinal fluid levels of markers of brain parenchymal damage in Vietnamese adults with severe malaria. 2005 , 99, 610-7		24
347	Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. 2005 , 111, 114-7		32
346	An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. 2005 , 296, 179-85		64
345	The neuropathology of Alzheimer's disease in the year 2005. 2005 , 433-440		11
344	Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. <i>Clinical Chemistry</i> , 2005 , 51, 189-95	5.5	137
343	CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. 2005 , 64, 1294-7		158
342	Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. 2005 , 6, 69-84		83
341	Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. 2005 , 11, 261-5		48
340	CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. 2005 , 5, 661-72		99
339	Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. <i>Neurobiology of Aging</i> , 2005 , 26, 1135-43	5.6	40

338	Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. 2006 , 22, 200-8		102
337	Axonal damage markers in cerebrospinal fluid are increased in ALS. 2006 , 66, 852-6		198
336	Neuropsychological and behavioural correlates of CSF biomarkers in dementia. 2006 , 48, 286-95		50
335	Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?. <i>Neuroscience Letters</i> , 2006 , 397, 83-7	3.3	68
334	Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. <i>Neurobiology of Aging</i> , 2006 , 27, 1202-11	5.6	53
333	Clinical Neuroproteomics of Human Body Fluids: CSF and Blood Assays for Early and Differential Diagnosis of Dementia. 2006 , 259-278		
332	. 2006 ,		3
331	Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. 2006 , 61, 755-8		73
330	Alzheimer's Disease and Other Disorders Associated With Dementia. 266-298		1
329	Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. 2006 , 20, 3723-35		133
328	Tau protein as a serum marker of brain damage in mild traumatic brain injury: preliminary results. 2006 , 23, 12-22		67
327	Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. 2006 , 127, 129-32		71
326	Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. 2006 , 63, 936-9		105
325	Biomarkers in the diagnosis of Alzheimer's disease: are we ready?. 2006 , 19, 172-9		44
324	Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. <i>Clinical Chemistry</i> , 2007 , 53, 859-65	5.5	58
323	Current state and future directions of neurochemical biomarkers for Alzheimer's disease. 2007 , 45, 1421-34		58
322	Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). <i>Neuroscience Letters</i> , 2007 , 417, 193-5	3.3	35
321	CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. 2007 , 23, 225-30		54

320	The association study between DHCR24 polymorphisms and Alzheimer's disease. 2007 , 144B, 906-10		18
319	Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. <i>European Journal of Neurology</i> , 2007 , 14, e1-26	6	400
318	Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. 2007 , 115, 325-30		38
317	[Neurobiological early diagnosis of Alzheimer's disease]. 2007 , 78, 1310-8		3
316	Tau missing from CSF: a case report. 2007 , 254, 107-9		4
315	Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia. 2007 , 254, 154-9		33
314	[Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia]. 2008 , 79, 891-2, 894-6, 898		2
313	Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. 2008 , 7 Suppl 1, 67-82		62
312	Cerebrospinal fluid tau and amyloid beta42 protein in patients with myotonic dystrophy type 1. <i>European Journal of Neurology</i> , 2008 , 15, 947-52	6	17
311	Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients. 2008 , 12, 334-41		17
310	Cerebrospinal fluid markers in Creutzfeldt-Jakob disease. 2008 , 5, 14		31
309	Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. <i>Neuroscience Letters</i> , 2008 , 436, 72-6	3.3	48
308	Genetic study evaluating LDLR polymorphisms and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008 , 29, 848-55	5.6	25
307	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008 , 29, 1143-59	5.6	181
306	Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. 2008 , 4, 38-48		349
305	Characterization of tau in cerebrospinal fluid using mass spectrometry. 2008 , 7, 2114-20		62
304	Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. 2008 , 5, 268-76		27
303	PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. 2008 , 26, 378-83		84

302	Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in patients with mild cognitive impairment. 2008 , 29, 1183-9		44
301	Tau as a biomarker of neurodegenerative diseases. <i>Biomarkers in Medicine</i> , 2008 , 2, 363-84	2.3	61
300	CSF studies facilitate DNA diagnosis in familial Alzheimer's disease due to a presenilin-1 mutation. <i>Journal of Alzheimer's Disease</i> , 2009 , 17, 53-7	4.3	5
299	Trabalho de consenso de força-tarefa da WFSBP sobre marcadores biológicos das demências: contribuição da análise do LCR e do sangue para o diagnóstico precoce e diferencial das demências. 2009 , 36, 1-16		1
298	Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. 2009 , 66, 382-9		607
297	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. 2009 , 46, 235-40		140
296	CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome. 2009 , 40, 42-9		32
295	Mild Alzheimer's disease: a "position paper". 2009 , 13, 503-19		8
294	Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis. 2009 , 53, 1264-70		16
293	Zn(II)- and Cu(II)-induced non-fibrillar aggregates of amyloid-beta (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. 2009 , 110, 1784-95		161
292	Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2009 , 16, 257-61	6	21
291	EFNS guidelines on disease-specific CSF investigations. <i>European Journal of Neurology</i> , 2009 , 16, 760-70	6	65
290	The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009 , 30, 672-81	5.6	65
289	CSF biomarker levels in early and late onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009 , 30, 1895-906	5.6	97
288	Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure. 2009 , 18, 474-7		42
287	Markers of Alzheimer's disease in a population attending a memory clinic. 2009 , 5, 307-17		49
286	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. 2009 , 302, 385-93		758
285	[Biomarkers for early diagnosis of Alzheimer's disease: current update and future directions]. 2009 , 165, 511-20		6

284	Diagnosis disclosure of prodromal Alzheimer disease-ethical analysis of two cases. 2010 , 37, 67-75		15
283	Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis: report of 2 cases. 2010 , 24, 108-14		10
282	CSF phospho-tau is independent of age, cognitive status and gender of neurological patients. 2010 , 257, 609-14		8
281	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. 2010 , 257, 2004-14		38
280	A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. 2010 , 220, 114-9		68
279	Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates. 2010 , 6, 25		40
278	Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. <i>European Journal of Neurology</i> , 2010 , 17, 90-6	6	53
277	Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. 2010 , 2010,		132
276	Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOE ϵ genotype. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 459-68	4-3	33
275	CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. 2010 , 30, 2088-101		164
274	CSF-tau and CSF-A β (1-42) in posterior cortical atrophy. 2010 , 29, 530-3		28
273	White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels. 2010 , 16, 58-69		24
272	Combination of P300 and CSF A β (1-42) assays may provide a potential tool in the early diagnosis of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2010 , 7, 295-9	3	23
271	Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. <i>BMC Neurology</i> , 2010 , 10, 51	3-1	36
270	Brain atrophy in healthy aging is related to CSF levels of A β (1-42). 2010 , 20, 2069-79		96
269	A β (1-42) Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible A β (1-42) aggregation?. 2010 , 223, 371-6		31
268	An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. 2010 , 223, 432-8		8
267	Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. 2010 , 6, 104-9		24

266	CSF biomarker pathology correlates with a medial temporo-parietal network affected by very mild to moderate Alzheimer's disease but not a fronto-striatal network affected by healthy aging. 2010 , 49, 1820-30		23
265	[Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice]. 2011 , 167, 474-84		10
264	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. 2011 , 5, 393-410		3
263	Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 25, 373-81	4-3	41
262	Amyloid- β the seeds of darkness. 2011 , 43, 1247-51		23
261	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 2011 , 496, 40-2	3-3	11
260	Cingulum fiber diffusivity and CSF T-tau in patients with subjective and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2011 , 32, 581-9	5-6	43
259	Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. 2011 , 3, 250-61		173
258	A novel progranulin mutation causing frontotemporal lobar degeneration with heterogeneous phenotypic expression. <i>Journal of Alzheimer's Disease</i> , 2011 , 23, 7-12	4-3	16
257	Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. <i>Journal of Alzheimer's Disease</i> , 2011 , 25, 739-45	4-3	43
256	Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 253-9	4-3	57
255	Cerebrospinal fluid biomarkers in Progranulin mutations carriers. <i>Journal of Alzheimer's Disease</i> , 2011 , 27, 781-90	4-3	42
254	Variability of the clinical phenotype in an Italian family with dementia associated with an intronic deletion in the GRN gene. <i>Journal of Alzheimer's Disease</i> , 2011 , 26, 583-90	4-3	10
253	A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia. <i>Journal of Alzheimer's Disease</i> , 2011 , 26, 19-26	4-3	27
252	Identifying and validating biomarkers for Alzheimer's disease. 2011 , 29, 26-32		321
251	Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. 2011 , 258, 1464-8		35
250	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. 2011 , 118, 259-62		41
249	Reduced CSF turnover and decreased ventricular A β 2 levels are related. 2011 , 12, 42		11

248	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. 2011 , 69, 570-80		310
247	Alzheimer's CSF markers in older schizophrenia patients. 2011 , 26, 640-8		21
246	State of the art in preservation of fluid biospecimens. 2011 , 9, 237-44		36
245	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. 2011 , 49, 353-66		108
244	Biomarkers in Alzheimer's disease. 2011 , 49, 773-8		6
243	Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. 2011 , 8, 202-7		23
242	Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. 2012 , 117, 284-92		20
241	PSEN1 mutation carriers present lower cerebrospinal fluid amyloid- β 2 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers. <i>Journal of Alzheimer's Disease</i> , 2012 , 30, 605-16	4.3	6
240	Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. 2012 , 33, 3738-44		25
239	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. 2012 , 8, 65-73		210
238	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. 2012 , 8, 520-7		29
237	Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. 2012 , 56, 494-9		8
236	Resting state fMRI in Alzheimer's disease: beyond the default mode network. <i>Neurobiology of Aging</i> , 2012 , 33, 1564-78	5.6	367
235	Metal ions as modulators of protein conformation and misfolding in neurodegeneration. 2012 , 256, 2253-2270	117	
234	Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. 2012 , 24, 244102		46
233	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012 , 6, 419-30	2.3	230
232	Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. <i>Biomarkers in Medicine</i> , 2012 , 6, 391-400	2.3	45
231	Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. <i>Journal of Alzheimer's Disease</i> , 2012 , 31, 447-52	4.3	59

230	Grey matter and cognitive patterns in cognitive impaired subjects using CSF biomarker cut-offs. <i>Journal of Alzheimer's Disease</i> , 2012 , 29, 741-9	4.3	1
229	The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. <i>Journal of Alzheimer's Disease</i> , 2012 , 32, 147-56	4.3	43
228	CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. 2012 , 47, 1-14		51
227	Increased concentration of the CSF Tau protein and its phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case report. 2012 , 119, 759-62		4
226	Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. <i>Neurological Sciences</i> , 2012 , 33, 375-8	3.5	18
225	Alzheimer CSF biomarkers in routine clinical setting. 2012 , 125, 416-23		27
224	Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β and total tau. 2013 , 4,		8
223	A SERS-based sandwich assay for ultrasensitive and selective detection of Alzheimer's tau protein. 2013 , 14, 3001-9		63
222	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. 2013 , 260, 640-50		42
221	Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study. <i>Neurobiology of Aging</i> , 2013 , 34, 1728-39	5.6	36
220	Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. 2013 , 74, 384-91		94
219	Cerebrospinal fluid tau protein as a biomarker for severity of spinal cord injury in dogs with intervertebral disc herniation. 2013 , 197, 253-8		31
218	Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. 2013 , 80, 1124-32		97
217	The missing link in the amyloid cascade of Alzheimer's disease - metal ions. 2013 , 62, 367-78		60
216	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. 2013 , 9, 677-86		43
215	Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. 2013 , 215, 234-40		36
214	Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. 2013 , 73, 449-58		111
213	Gold Nanostructure LSPR-Based Biosensors for Biomedical Diagnosis. 2013 , 171-188		2

212	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. 2013 , 28, 738-44		19
211	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. 2013 , 80, 1048-56		131
210	Mild cognitive impairment: cerebrospinal fluid tau biomarker pathologic levels and longitudinal changes in white matter integrity. 2013 , 266, 295-303		40
209	Identification of an important potential confound in CSF AD studies: aliquot volume. 2013 , 51, 2311-7		36
208	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. 2013 , 43, 911-20		72
207	Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study. <i>PLoS ONE</i> , 2013 , 8, e79378	3-7	59
206	Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013 , 3, 291-300	2-5	33
205	The presenilin 1 P264L mutation presenting as non-fluent/agrammatic primary progressive aphasia. <i>Journal of Alzheimer's Disease</i> , 2013 , 36, 239-43	4-3	12
204	Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. 2013 , 18, 1150-73		15
203	Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 723-36	4-3	80
202	Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism. <i>Journal of Alzheimer's Disease</i> , 2014 , 38, 747-52	4-3	12
201	Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex. 2013 , 2013, 679089		
200	Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS. <i>PLoS ONE</i> , 2014 , 9, e103811	3-7	95
199	Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease. 2014 , 4,		6
198	Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia. <i>Journal of Alzheimer's Disease</i> , 2015 , 43, 1429-40	4-3	20
197	Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 919-27	4-3	27
196	Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease. 2014 , 54, 739-47		8
195	White matter integrity and cognition in Parkinson's disease: a cross-sectional study. 2014 , 4, e003976		31

194	Electroanalytical Sensors and Methods for Assays and Studies of Neurological Biomarkers. 2014 , 26, 1236-1248		6
193	Modulation of β amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 19	9	25
192	Multiple cancers in a patient with common variable immunodeficiency. 2014 , 42, 85-7		1
191	Medial temporal atrophy in early and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014 , 35, 2004-12	5.6	46
190	Electroanalytical and surface plasmon resonance sensors for detection of breast cancer and Alzheimer's disease biomarkers in cells and body fluids. 2014 , 139, 1814-25		39
189	Neuropathology of prodromal Lewy body disease. 2014 , 29, 410-5		56
188	Trace vapour detection at room temperature using Raman spectroscopy. 2014 , 139, 1960-6		7
187	Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid- β in cerebrospinal fluid. <i>Clinical Chemistry</i> , 2014 , 60, 987-94	5.5	109
186	Amyloid- β -induced action potential desynchronization and degradation of hippocampal gamma oscillations is prevented by interference with peptide conformation change and aggregation. 2014 , 34, 11416-25		61
185	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. 2014 , 10, 808-17		132
184	White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults. <i>Neurobiology of Aging</i> , 2014 , 35, 2263-71	5.6	45
183	Tau protein levels in children do not increase during severe asthma attack-induced hypoxic conditions. 2014 , 42, 83-5		
182	Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy. 2014 , 15, 614-8		16
181	Zinc ion induced prefibrillar oligomerization of A β peptides: From nanocoin to nanobelt. 2014 , 608, 201-206		2
180	Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis. 2014 , 6, 287		33
179	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid- β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 175-87	4.3	38
178	T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 619-28	4.3	17
177	Endostatin level in cerebrospinal fluid of patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 1253-61	4.3	16

176	The Possible Role of Craniocervical Trauma and Abnormal Cerebrospinal Fluid Hydrodynamics in the Genesis of Multiple Sclerosis and the Craniocervical Syndrome. 74-91		1
175	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 291-317	4.3	61
174	Bivariate correlation coefficients in family-type clustered studies. 2015 , 57, 1084-109		11
173	A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease. <i>Journal of Clinical Neurology (Korea)</i> , 2015 , 11, 132-41	1.7	13
172	Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 271-6	4.3	19
171	First administration of the Fc-attenuated anti- β -amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. <i>PLoS ONE</i> , 2015 , 10, e0098153	3.7	20
170	Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study. 2015 , 53, 453-60		10
169	Lateral ventricular cerebrospinal fluid diffusivity as a potential neuroimaging marker of brain temperature in multiple sclerosis: a hypothesis and implications. 2015 , 33, 262-9		9
168	Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment. 2015 , 131, 139-47		18
167	Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers. 2015 , 49, 182-7		34
166	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. 2015 , 138, 2701-15		86
165	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. 2015 , 449, 9-15		51
164	Cerebrospinal fluid tau proteins in status epilepticus. 2015 , 49, 150-4		24
163	Cerebrospinal fluid biomarkers for Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion. 2015 , 39, 287-93		15
162	Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. <i>Clinical Chemistry</i> , 2015 , 61, 734-43	5.5	47
161	Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. 2015 , 16, 388-92		16
160	Blood-based Amyloid and Tau Biomarker Tests For Alzheimer's Disease. 2016 , 4, 4-13		
159	Reference Intervals for Plasma Amyloid β In Korean Adults Without Cognitive Impairment. 2016 , 36, 595-8		4

158	Alzheimer's Biomarkers are Correlated with Brain Connectivity in Older Adults Differentially during Resting and Task States. 2016 , 8, 15		22
157	Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. 2016 , 6, 413-21		9
156	Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 1385-1393	4.3	6
155	Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 615-33	4.3	18
154	Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 1495-1508	4.3	17
153	Estandarizaci3n de aspectos preanal3ticos para el estudio de biomarcadores de la enfermedad de Alzheimer en el l3quido cefalorraqu3deo. 2016 , 9, 184-188		
152	PET Imaging of Tau Deposition in the Aging Human Brain. 2016 , 89, 971-982		619
151	Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 17	9	75
150	Alpha-mannosidosis: characterization of CNS pathology and correlation between CNS pathology and cognitive function. 2016 , 89, 489-494		7
149	Symptomatic and preclinical Alzheimer's disease: Neuropathology and imaging. 2016 , 22, 127-131		1
148	Novel PSEN1 mutations (H214N and R220P) associated with familial Alzheimer's disease identified by targeted exome sequencing. <i>Neurobiology of Aging</i> , 2016 , 40, 192.e7-192.e11	5.6	13
147	Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. 2016 , 12, 577-89		50
146	A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations. <i>Neurobiology of Aging</i> , 2017 , 49, 219.e5-219.e13	5.6	4
145	The APOE4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. 2017 , 6, 50-59		29
144	Mitochondrial transcription factor A (TFAM) rs1937 and AP endonuclease 1 (APE1) rs1130409 alleles are associated with reduced cognitive performance. <i>Neuroscience Letters</i> , 2017 , 645, 46-52	3.3	9
143	A Translational Systems Pharmacology Model for APOE Kinetics in Mouse, Monkey, and Human. 2017 , 6, 666-675		7
142	Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea. 2017 , 31, 13-18		16
141	Clinical validity of cerebrospinal fluid APOE4, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017 , 52, 196-213	5.6	73

140	Expanding the cerebrospinal fluid endopeptidome. 2017 , 17, 1600384		23
139	Tau protein (MAPT) as a possible biochemical marker of traumatic brain injury in postmortem examination. 2017 , 280, 1-7		20
138	Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. 2017 , 7, e00776		22
137	Cerebrospinal Fluid Amyloid- β 2, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 183-200	4.3	25
136	A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. 2017 , 6, 15-24		141
135	Alzheimer's disease markers in the aged sheep (<i>Ovis aries</i>). <i>Neurobiology of Aging</i> , 2017 , 58, 112-119	5.6	17
134	A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 1359-1379	4.3	47
133	Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 135-143	4.3	8
132	Cerebrospinal fluid A β 2, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis. 2017 , 14, 13		30
131	No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau). 2017 , 8, 599-604		8
130	Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017 , 7, 1-14	2.5	36
129	Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 577-583	4.3	1
128	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 84	9	42
127	Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease. 2017 , 9, 9		17
126	Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults. 2017 , 9, 51		12
125	Identification of Successful Cognitive Aging in the Alzheimer's Disease Neuroimaging Initiative Study. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 101-111	4.3	20
124	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 201-210	4.3	6
123	Age-dependent changes in synaptic plasticity enhance tau oligomerization in the mouse hippocampus. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 67	7.3	7

122	Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016 , 6, 465-476	2.5	5
121	FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. 2018 , 18, 167-177		65
120	Concordance between brain 18F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease. 2018 , 37, 3-8		
119	Tau Kinetics in Neurons and the Human Central Nervous System. 2018 , 97, 1284-1298.e7		208
118	Concordance between brain F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease. 2018 , 37, 3-8		2
117	Temporal association patterns and dynamics of amyloid- β and tau in Alzheimer's disease. 2018 , 33, 657-666		15
116	Modeling of Glutamate Pathway in Alzheimer's Disease using Biochemical Systems Theory. 2018 ,		1
115	Cerebrospinal fluid neurogranin/ β -site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. 2018 , 4, 617-627		17
114	Next-generation biomarker discovery in Alzheimer's disease using metabolomics - from animal to human studies. 2018 , 10, 1525-1546		21
113	Clinical Experience with Cerebrospinal Fluid A β 2, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 1417-1425	4.3	10
112	Dissociation of cerebrospinal fluid amyloid- β and tau levels in patients with prolonged posttraumatic disorders of consciousness. 2018 , 32, 1056-1060		5
111	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. 2018 , 14, 1313-1333		61
110	Molecular Markers of Early Diagnosis of Alzheimer Disease: Prospects for Research in Peripheral Tissues. 2018 , 8, 111-118		2
109	Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	101
108	A biomarker study in long-lasting amnesic mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 42	9	19
107	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 79	9	31
106	[18F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [18F]-Fludeoxyglucose. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1595-1607	4.3	13
105	BDNF and Tau as biomarkers of severity in multiple sclerosis. <i>Biomarkers in Medicine</i> , 2018 , 12, 717-726	2.3	11

104	Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias. 2019 ,		4
103	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. 2019 , 23, 101895		21
102	Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF. 2019 , 11, 282		5
101	Cerebrospinal fluid amyloid levels are associated with delayed memory retention in cognitively normal biomarker-negative older adults. <i>Neurobiology of Aging</i> , 2019 , 84, 90-97	5.6	3
100	Sex determination in cremated human remains using the lateral angle of the pars petrosa ossis temporalis: is old age a limiting factor?. 2019 , 15, 392-398		7
99	Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. 2019 , 16, 28		1
98	Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: A systematic literature review. 2019 , 107, 346-359		17
97	The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease. 2019 , 25, 661-672		15
96	Biochemical markers of time since death in cerebrospinal fluid: A first step towards. 2019 , 56, 274-286		7
95	Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions. 2019 , 92, e2717-e2726		8
94	Concentration of microtubule associated protein tau (MAPT) in urine and saliva as a potential biomarker of traumatic brain injury in relationship with blood-brain barrier disruption in postmortem examination. 2019 , 301, 28-36		8
93	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 263-276	4.3	6
92	Glial activation and inflammation along the Alzheimer's disease continuum. 2019 , 16, 46		97
91	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2019 , 97, 3-17	4.8	51
90	Functional and morphological changes of the retinal vessels in Alzheimer's disease and mild cognitive impairment. <i>Scientific Reports</i> , 2019 , 9, 63	4.9	65
89	In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. <i>Journal of Alzheimer's Disease</i> , 2019 , 67, 715-723	4.3	5
88	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. <i>Neurobiology of Aging</i> , 2019 , 75, 42-50	5.6	26
87	Serum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis. <i>Medical Hypotheses</i> , 2020 , 135, 109476	3.8	7

86	Brain metabolic signatures across the Alzheimer's disease spectrum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 256-269	8.8	13
85	Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 121	9	2
84	The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 387-394	4.3	1
83	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	4
82	BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 313-322	4.3	3
81	Neuro-Retina Might Reflect Alzheimer's Disease Stage. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1455-1468	4.3	4
80	Revisiting the Amyloid Cascade Hypothesis: From Anti-A β Therapeutics to Auspicious New Ways for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	42
79	No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study. <i>BMC Neurology</i> , 2020 , 20, 174	3.1	14
78	Individual Brain Metabolic Signatures in Corticobasal Syndrome. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 517-528	4.3	5
77	Analysis of Tau-441 protein in clinical samples using rGO/AuNP nanocomposite-supported disposable impedimetric neuro-biosensing platform: Towards Alzheimer's disease detection. <i>Talanta</i> , 2020 , 219, 121257	6.2	8
76	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. <i>BMC Medicine</i> , 2020 , 18, 140	11.4	16
75	Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia. <i>Frontiers in Neurology</i> , 2020 , 11, 560	4.1	0
74	Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study. <i>Molecular Neurodegeneration</i> , 2020 , 15, 25	19	21
73	The Interplay between Diabetes and Alzheimer's Disease-In the Hunt for Biomarkers. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
72	Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases. <i>Brain Sciences</i> , 2020 , 10,	3.4	7
71	Stability of Plasma Amyloid- β -40, Amyloid- β -42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2020 , 10, 46-55	2.5	5
70	Biomarker-based stability in limbic-predominant amnesic mild cognitive impairment. <i>European Journal of Neurology</i> , 2021 , 28, 1123-1133	6	3
69	Dynamic functional networks in idiopathic normal pressure hydrocephalus: Alterations and reversibility by CSF tap test. <i>Human Brain Mapping</i> , 2021 , 42, 1485-1502	5.9	4

68	Singular cases of Alzheimer's disease disclose new and old genetic "acquaintances". <i>Neurological Sciences</i> , 2021 , 42, 2021-2029	3.5	2
67	Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease. <i>Journal of Nanobiotechnology</i> , 2021 , 19, 72	9.4	10
66	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2121-2139	8.8	18
65	Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?. <i>International Journal of Legal Medicine</i> , 2021 , 135, 2081-2089	3.1	1
64	Tau assemblies do not behave like independently acting prion-like particles in mouse neural tissue. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 41	7.3	3
63	Diagnose it yourself: will there be a home test kit for Alzheimer's disease?. <i>Neurodegenerative Disease Management</i> , 2021 , 11, 167-176	2.8	
62	Biomarkers and Their Implications in Alzheimer's Disease: A Literature Review. <i>Exploratory Research and Hypothesis in Medicine</i> , 2021 , 000, 000-000	1	1
61	The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease. <i>Scientific Reports</i> , 2021 , 11, 13050	4.9	3
60	Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer's disease drug in China.. <i>Journal of Pharmaceutical Analysis</i> , 2022 , 12, 145-155	14	3
59	Progression of cortical dysfunction in CSF1R-related leukoencephalopathy detected using single-photon emission computed tomography. <i>Neurology and Clinical Neuroscience</i> , 2021 , 9, 369-375	0.3	
58	Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 8419-8431	5.6	3
57	Regional brain volumes relate to Alzheimer's disease cerebrospinal fluid biomarkers and neuropsychometry: A cross-sectional, observational study. <i>PLoS ONE</i> , 2021 , 16, e0254332	3.7	2
56	Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid- β -40: A Correlational Study in Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 155-162	4.3	1
55	Millipore xMap [®] Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid. <i>Frontiers in Psychiatry</i> , 2021 , 12, 716686	5	1
54	Point of care testing of sports biomarkers: Potential applications, recent advances and future outlook. <i>TrAC - Trends in Analytical Chemistry</i> , 2021 , 142, 116327	14.6	6
53	Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington's disease.		
52	Potential Biomarkers Associated with Multiple Sclerosis Pathology. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
51	Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103231	4	6

50	Diagnostic biomarkers in Alzheimer's disease. <i>Biomarkers in Neuropsychiatry</i> , 2021 , 5, 100041	3.8	2
49	Tau assemblies do not behave like independently acting prion-like particles in mouse neural tissue.		
48	Peripheral Biomarkers in Dementia and Alzheimer's Disease. 2009 , 3-12		3
47	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease.		2
46	Tau protein as a possible marker of cerebrospinal fluid leakage in cerebrospinal fluid rhinorrhoea: A pilot study. <i>Biochemia Medica</i> , 2017 , 27, 030703	2.5	5
45	Expression of Tau40 induces activation of cultured rat microglial cells. <i>PLoS ONE</i> , 2013 , 8, e76057	3.7	34
44	Differential white matter connectivity in early mild cognitive impairment according to CSF biomarkers. <i>PLoS ONE</i> , 2014 , 9, e91400	3.7	12
43	The nonlinear relationship between cerebrospinal fluid A β 2 and tau in preclinical Alzheimer's disease. <i>PLoS ONE</i> , 2018 , 13, e0191240	3.7	23
42	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. <i>Molecular Systems Biology</i> , 2020 , 16, e9356	12.2	47
41	The Clinical Issues. 2016 , 19-50		1
40	CSF tau and β amyloid as biomarkers for mild cognitive impairment. <i>Dialogues in Clinical Neuroscience</i> , 2004 , 6, 379-90	5.7	16
39	Biological markers for early detection and pharmacological treatment of Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2009 , 11, 141-57	5.7	31
38	Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts. <i>Frontiers in Neurology</i> , 2020 , 11, 1021	4.1	3
37	Cerebrospinal Fluid Levels of β Amyloid 40 and β Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients. <i>Journal of Clinical Neurology (Korea)</i> , 2019 , 15, 353-359	1.7	5
36	Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. <i>World Journal of Psychiatry</i> , 2011 , 1, 8-18	3	27
35	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. <i>Scientific Reports</i> , 2021 , 11, 20375	4.9	0
34	Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression. <i>Frontiers in Immunology</i> , 2021 , 12, 737944	8.4	0
33	Laborchemische Diagnostik und therapeutisches Drugmonitoring. 2008 , 511-528		1

32 Disease-Specific Cerebrospinal Fluid Investigations. 175-197

31 BDNF and Tau as biomarkers of severity in Multiple Sclerosis.

30 Association between single moderate to severe traumatic brain injury and long-term tauopathy in humans and preclinical animal models: a systematic narrative review of the literature.. *Acta Neuropathologica Communications*, **2022**, 10, 13

7.3 0

29 Kappa/Lambda light-chain typing in Alzheimer's Disease.. *Current Alzheimer Research*, **2022**,

3 1

28 Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?. *Journal of Alzheimer's Disease*, **2021**,

4.3 1

27 Plasma p-tau181/A β -42 ratio predicts A β PET status and correlates with CSF-p-tau181/A β -42 and future cognitive decline.

26 The Role of Tau beyond Alzheimer's Disease: A Narrative Review.. *Biomedicines*, **2022**, 10,

4.8 0

25 Exploration of salient risk factors involved in mild cognitive impairment.. *European Journal of Neuroscience*, **2022**,

3.5 0

24 Long-term stability and age-dependence of six regulatory serum proteins.. *Biomarkers in Medicine*, **2022**,

2.3 0

23 Image_1.pdf. **2020**,

22 Image_2.pdf. **2020**,

21 Image_3.pdf. **2020**,

20 Image_4.pdf. **2020**,

19 Table_1.docx. **2020**,

18 Table_2.xlsx. **2020**,

17 Table_3.xlsx. **2020**,

16 Table_4.docx. **2020**,

15 Table_5.docx. **2020**,

14	Table_6.docx. 2020 ,		
13	Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3.. <i>European Journal of Neurology</i> , 2022 ,	6	3
12	Current and Future Biomarkers in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5877	6.3	1
11	Modulation of MAPK- and PI3/AKT-Dependent Autophagy Signaling by Stavudine (D4T) in PBMC of Alzheimer's Disease Patients. <i>Cells</i> , 2022 , 11, 2180	7.9	1
10	Predictive value of phospho-tau/total-tau ratio in amyloid-negative Mild Cognitive Impairment. <i>Neuroscience Letters</i> , 2022 , 136811	3.3	0
9	Proteomic Markers and Early Prediction of Alzheimer's Disease. 2022 , 87, 762-776		
8	Stable CSF neurogranin and BACE1 levels differentiate predementia Alzheimer's disease patients.		0
7	The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death. 2022 , 190, 204-217		2
6	Plasma p-tau181/A β -42 ratio predicts A β PET status and correlates with CSF-p-tau181/A β -42 and future cognitive decline. 2022 , 14,		0
5	Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer's disease compared to neurological disease controls: a retrospective study on 276 patients.		0
4	The Frontal Assessment Battery (FAB) effectively discriminates between MCI and dementia within the clinical spectrum of neurochemically confirmed Alzheimer's disease. 13,		0
3	Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum. 2022 , 17,		0
2	Lower semantic fluency scores and a phonemic-over-semantic advantage predict abnormal CSF P-tau181 levels in A β patients within the Alzheimer's disease clinical spectrum.		0
1	Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280-acetylated tau in cell and mouse models. 2023 , 133,		0